84 related articles for article (PubMed ID: 19283661)
1. Diabetes enhances the expression of H-ras and suppresses the expression of EGFR leading to increased cell proliferation.
Vairaktaris E; Goutzanis L; Yapijakis C; Vassiliou S; Spyridonidou S; Vylliotis A; Nkenke E; Lazaris AC; Strantzias P; Patsouris E
Histol Histopathol; 2009 May; 24(5):531-9. PubMed ID: 19283661
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats.
Vairaktaris E; Goutzanis L; Vassiliou S; Spyridonidou S; Nkenke E; Papageorgiou G; Strantzias P; Lazaris A; Yapijakis C; Patsouris E
J Cancer Res Clin Oncol; 2008 Mar; 134(3):337-44. PubMed ID: 17704947
[TBL] [Abstract][Full Text] [Related]
3. Diabetes and oral oncogenesis.
Vairaktaris E; Spyridonidou S; Goutzanis L; Vylliotis A; Lazaris A; Donta I; Perrea D; Yapijakis C; Patsouris E
Anticancer Res; 2007; 27(6B):4185-93. PubMed ID: 18225590
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of oral cancer in diabetic animals is not associated with c-jun activation pathway.
Vairaktaris E; Goutzanis L; Kalokerinos G; Vassiliou S; Spyridonidou S; Avgoustidis D; Strantzias P; Lazaris A; Papageorgiou G; Ragos V; Yapijakis C; Patsouris E
J Craniomaxillofac Surg; 2007 Dec; 35(8):382-7. PubMed ID: 18023197
[TBL] [Abstract][Full Text] [Related]
5. Diabetes increases both N-ras and ets-1 expression during rat oral oncogenesis resulting in enhanced cell proliferation and metastatic potential.
Vairaktaris E; Goutzanis L; Kalokerinos G; Yannopoulos A; Yapijakis C; Vassiliou S; Spyridonidou S; Vylliotis A; Nkenke E; Lazaris AC; Tesseromatis C; Patsouris E
In Vivo; 2007; 21(4):615-21. PubMed ID: 17708355
[TBL] [Abstract][Full Text] [Related]
6. Diabetes enhances cell proliferation but not Bax/Bcl-2-mediated apoptosis during oral oncogenesis.
Vairaktaris E; Kalokerinos G; Goutzanis L; Yapijakis C; Derka S; Vassiliou S; Spyridonidou S; Vylliotis A; Nkenke E; Lazaris A; Patsouris E
Int J Oral Maxillofac Surg; 2008 Jan; 37(1):60-5. PubMed ID: 17825529
[TBL] [Abstract][Full Text] [Related]
7. The hamster model of sequential oral oncogenesis.
Vairaktaris E; Spyridonidou S; Papakosta V; Vylliotis A; Lazaris A; Perrea D; Yapijakis C; Patsouris E
Oral Oncol; 2008 Apr; 44(4):315-24. PubMed ID: 18061531
[TBL] [Abstract][Full Text] [Related]
8. Analysis of activated EGFR signalling pathways and their relation to laminin-5 gamma2 chain expression in oral squamous cell carcinoma (OSCC).
Richter P; Böhmer FD; Hindermann W; Borsi L; Hyckel P; Schleier P; Katenkamp D; Kosmehl H; Berndt A
Histochem Cell Biol; 2005 Aug; 124(2):151-60. PubMed ID: 16052324
[TBL] [Abstract][Full Text] [Related]
9. Expression of cell cycle regulator p16 is not affected by diabetes during oral oncogenesis.
Vairaktaris E; Goutzanis L; Nkenke E; Spyridonidou S; Vassiliou S; Derka S; Vylliotis A; Yapijakis C; Lazaris A; Patsouris E
In Vivo; 2007; 21(5):745-50. PubMed ID: 18019407
[TBL] [Abstract][Full Text] [Related]
10. H-ras and c-fos exhibit similar expression patterns during most stages of oral oncogenesis.
Vairaktaris E; Papakosta V; Derka S; Vassiliou S; Nkenke E; Spyridonidou S; Vylliotis A; Lazaris A; Kokkori A; Moulavassili P; Loukeri S; Perrea D; Donta I; Yapijakis C; Patsouris E
In Vivo; 2008; 22(5):621-8. PubMed ID: 18853758
[TBL] [Abstract][Full Text] [Related]
11. Diabetes alters expression of p53 and c-myc in different stages of oral oncogenesis.
Vairaktaris E; Kalokerinos G; Goutzanis L; Spyridonidou S; Vassiliou S; Derka S; Nkenke E; Yapijakis C; Vylliotis A; Lazaris A; Patsouris E
Anticancer Res; 2007; 27(3B):1465-73. PubMed ID: 17595763
[TBL] [Abstract][Full Text] [Related]
12. Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Goutzanis L; Vairaktaris E; Yapijakis C; Kavantzas N; Nkenke E; Derka S; Vassiliou S; Acil Y; Kessler P; Stavrianeas N; Perrea D; Donta I; Skandalakis P; Patsouris E
Oral Oncol; 2007 Feb; 43(2):165-73. PubMed ID: 16860589
[TBL] [Abstract][Full Text] [Related]
13. EGFR and c-Jun exhibit the same pattern of expression and increase gradually during the progress of oral oncogenesis.
Vairaktaris E; Loukeri S; Vassiliou S; Nkenke E; Spyridonidou S; Vylliotis A; Papakosta V; Lazaris A; Agrogiannis G; Yapijakis C; Perrea D; Patsouris E
In Vivo; 2007; 21(5):791-6. PubMed ID: 18019413
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation.
Huang S; Zhang A; Ding G; Chen R
Am J Physiol Renal Physiol; 2009 Jun; 296(6):F1323-33. PubMed ID: 19339632
[TBL] [Abstract][Full Text] [Related]
15. Diabetes does not influence oral oncogenesis through fibroblast growth factor receptors.
Vairaktaris E; Goutzanis L; Nkenke E; Spyridonidou S; Vassiliou S; Derka S; Vylliotis A; Yapijakis C; Lazaris A; Strantzias P; Kalimeras E; Patsouris E
In Vivo; 2007; 21(4):623-8. PubMed ID: 17708356
[TBL] [Abstract][Full Text] [Related]
16. The EGF receptor activates ERK but not JNK Ras-dependently in basal conditions but ERK and JNK activation pathways are predominantly Ras-independent during cardiomyocyte stretch.
Duquesnes N; Vincent F; Morel E; Lezoualc'h F; Crozatier B
Int J Biochem Cell Biol; 2009 May; 41(5):1173-81. PubMed ID: 19015044
[TBL] [Abstract][Full Text] [Related]
17. Diabetes regulates small molecular weight G-protein, H-Ras, in the microvasculature of the retina: implication in the development of retinopathy.
Kanwar M; Kowluru RA
Microvasc Res; 2008 Nov; 76(3):189-93. PubMed ID: 18514235
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
19. Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways.
Zhen L; Fan D; Yi X; Cao X; Chen D; Wang L
Int J Clin Exp Pathol; 2014; 7(10):6438-46. PubMed ID: 25400722
[TBL] [Abstract][Full Text] [Related]
20. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
